Search clinical trials for: No Ranibizumab

Total 7196 results

Sun Yat-sen University

Terminated

Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy

Polypoidal Choroidal Vasculopathy

China
California Retina Consultants

Unknown

Analysis of Aqueous and Vitreous Humor (ARK)

Macular Degeneration | Proliferative Diabetic Retinopathy | Neovascular Glaucoma | Macular Hole

United States
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Unknown

601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)

Branch Retinal Vein Occlusion

China
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Unknown

601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)

Central Retinal Vein Occlusion

China
Shanghai General Hospital, Shanghai Jiao Tong University...
RenJi Hospital; Shanghai 10th People's Hospital; Eye & ENT Hospital of Fudan... and other collaborators

Unknown

Multicenter Clinical Study of Anti-VEGF Treatment on High Risk Diabetic Retinopathy (DR)

Diabetic Retinopathy | Ranibizumab

China
University of Campania "Luigi Vanvitelli"

Completed

Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia

Myopia, Degenerative
Hanscom, Thomas, M.D.
Genentech, Inc.

Completed

Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab (RAVEN)

Central Retinal Vein Occlusion | Macular Edema | Branch Retinal Vein Occlusion

United States
University of Illinois at Chicago
Genentech, Inc.

Withdrawn

Lucentis for New Onset Neovascular Glaucoma (NVG)

Glaucoma | Neovascular Glaucoma | New Onset Glaucoma | New Onset Neovascular Glaucoma
Especialistas en Retina Medica y Quirurgica Grupo...
Centro de Retina Medica y Quirurgica S.C.

Completed

MIcrodoses of raNIbizumab in Diabetic MAcular Edema (MINIMA-2) (MINIMA-2)

Diabetic Macular Edema

Argentina, Mexico
Lupin Ltd.

Recruiting

Study to Compare Efficacy and Safety of LUBT010 and Lucentis® in Patients With Neovascular AMD

Neovascular Age-related Macular Degeneration

India
Hawaii Pacific Health
Genentech, Inc.

Completed

Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2) (PEARL2)

Polypoidal Choroidal Vasculopathy | PCV

United States
New England Retina Associates
Genentech, Inc.

Completed

Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)

Choroidal Melanoma

United States
Samsung Bioepis Co., Ltd.

Completed

A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Age-Related Macular Degeneration

Korea, Republic of, United States, India, Germany, Hungary, United Kingdom, Czechia, Poland, Russian Federation
Instituto de Olhos de Goiania

Completed

Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema

Retinal Diseases
Peter A Campochiaro, MD
Genentech, Inc.

Completed

Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions (RELATE)

Retinal Vein Occlusion

United States
Pusan National University Hospital
Novartis

Completed

Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab

Exudative Age-related Macular Degeneration

Korea, Republic of
Vista Klinik

Completed

SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia

Age Related Macular Degeneration | Choroidal Neovascularization

Switzerland
Novartis

Completed

Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD) (EXCITE)

Age Related Macular Degeneration

Switzerland
Hoffmann-La Roche

Recruiting

A Study Of The Efficacy, Safety, And Pharmacokinetics Of The Port Delivery System With Ranibizumab In Chinese Patients With Neovascular Age-Related Macular Degeneration

Neovascular Age Related Macular Degeneration | nAMD

China
Attila Vajas
Semmelweis University

Unknown

Safety and Efficacy of Intravitreal Ranibizumab as a Preoperative Adjunct Treatment Before Vitrectomy Surgery in Proliferative Diabetic Retinopathy (PDR) Compared to Vitrectomy Alone (VITARM)

Diabetic Retinopathy

Hungary
Novartis

Completed

Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center Involvement (RESOLVE)

Diabetic Macular Edema

Switzerland
Genentech, Inc.

Recruiting

A Study Assessing Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS) (Belvedere)

Neovascular Age-related Macular Degeneration

United States
Sun Yat-sen University

Completed

Comparison of PDT, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN Regimen

Polypoidal Choroidal Vasculopathy

China
AbbVie

Recruiting

Pivotal 1 Study of RGX-314 Gene Therapy in Participants With nAMD (ATMOSPHERE)

CNV | AMD | nAMD | Wet AMD | Wet Age-related Macular Degeneration | wAMD

United States
Genentech, Inc.

Completed

A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO) (BRAVO)

Macular Edema | Retinal Vein Occlusion
David M. Brown, M.D.
Novartis Pharmaceuticals

Terminated

Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration

Age-Related Macular Degeneration

United States
University Hospital, Basel, Switzerland

Completed

Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV

Age-Related Macular Degeneration | Choroidal Neovascularization

Switzerland
Beijing Hospital

Completed

Combination of Intravitreal Ranibizumab With or Without Micropulse Laser for the Treatment of DME

Diabetic Macular Edema

China
Genentech, Inc.

Completed

A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE) (CRUISE)

Macular Edema | Retinal Vein Occlusion
Hoffmann-La Roche

Active, not recruiting

This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With Intravitreal Ranibizumab (Pagoda)

Diabetic Macular Edema

United States
Peter A Campochiaro, MD
Genentech, Inc.

Completed

Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions (LVO)

Macular Edema | Retinal Vein Occlusion

United States
Dongyang People's Hospital

Recruiting

Manage Macular Cystoid Edema With Retinal Vein Obstruction Using Traditional Chinese Medicine and Ranibizumab (JQMMT+RA)

Macular Cystoid Edema

China
Poitiers University Hospital

Completed

Intravitreal Injections of Ranibizumab With Deferred Laser Grid Laser Photocoagulation for Treatment of Diabetic Macular Edema With Visual Impairment

Diabetic Macular Edema

France
Philip J. ferrone, M.D.

Completed

Study Comparing 0.5mg of Ranibizumab and Higher Doses in the Treatment of Clinically Significant Diabetic Macular Edema

Clinically Significant Diabetic Macular Edema

United States
University of Zurich

Completed

VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD)

Macular Degeneration

Switzerland
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia (Brilliance)

Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)

China, India, Thailand, Hong Kong, Korea, Republic of, Philippines
Mid-Atlantic Retina Consultations, Inc.

Completed

Photodynamic and Pharmacologic Treatment of CNV (PBS)

Macular Degeneration | Choroidal Neovascularization
Aleris Helse
Novartis

Completed

A Randomized Study Comparing Ranibizumab to Sham in Patients With Macular Edema Secondary to CRVO

Central Retinal Vein Occlusion | Macular Edema

Norway
Ophthalmic Consultants of Boston
Genentech, Inc.

Completed

Safety Study of Ranibizumab Eye Injections to Treat Choroidal Neovascularization That Was Caused Other Than by Age-Related Macular Degeneration.

Choroidal Neovascularization
Hoffmann-La Roche

Active, not recruiting

A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (PAVILION)

Diabetic Retinopathy

United States, Puerto Rico
Pusan National University Hospital
Novartis

Unknown

Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy (CyPov)

Polypoidal Choroidal Vasculopathy | Exudative Age-related Macular Degeneration

Korea, Republic of
The New York Eye Cancer Center
Genentech, Inc.

Completed

Effect of Ranibizumab on Malignant Conjunctival Neoplasia

Conjunctival Neoplasms

United States
University of Luebeck

Completed

Ranibizumab Short- and Log-term Effects on Retinal Function in wAMD (LucERG)

Age-Related Macular Degeneration | Retinal Function

Germany
Universiti Sains Malaysia

Completed

Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study

Pterygium
University of Miami
Genentech, Inc.

Completed

Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular Edema

Uveitic Cystoid Macular Edema

United States
Tokyo Medical University

Unknown

Development of Intravitreal Ranibizumab by Determining the Pathogenesis of Macular Edema With Retinal Vein Occlusion

Central Retinal Vein Occlusion | Macular Edema | Branch Retinal Vein Occlusion

Japan
Retina Associates of Kentucky
Genentech, Inc.

Unknown

Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome (IVL for OHS)

Ocular Histoplasmosis Syndrome

United States
Hoffmann-La Roche

Completed

A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration (Archway)

Neovascular Age-Related Macular Degeneration

United States
Novartis Pharmaceuticals

Completed

Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye (TWEYES)

Wet Age Related Macular Degeneration

Italy
University of Colorado, Denver
Genentech, Inc.

Completed

Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy (NAION)

Nonarteritic Anterior Ischemic Optic Neuropathy

United States

3

Subscribe